Identification and characterization of a BER-2/neu epitope as a potential target for cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 59, Issue 5, 2010, Pages 715-727

  Lekka, Eftychia ^a   Gritzapis, Angelos D ^a   Perez, Sonia A ^a   Tsavaris, Nikolaos ^b   Missitzis, Ioannis ^a   Mamalaki, Avgi ^c   Papamichail, Michael ^a   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

Breast cancer; CTL; HER 2 neu; Hhd mice; Peptide vaccines

Indexed keywords

AMINO ACID; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GLUTAMINYLISOLEUCYLALANYLLYSYLGLYCYLMETHIONYLSERYLTYROSYLLEUCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; HLA ANTIGEN CLASS 1; PEPTIDE VACCINE; UNCLASSIFIED DRUG; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; BINDING ASSAY; BREAST CANCER; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG STABILITY; DRUG TARGETING; EX VIVO STUDY; HUMAN; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION; ANIMAL; BREAST TUMOR; CELL SEPARATION; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CELL SEPARATION; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77950492892     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0791-7     Document Type: Article

References (57)

1. Rötzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee HG (1990) Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348(6298):252-254 (Pubitemid 20383092)
2. Wallny HJ, Rammensee HG (1990) Identification, of classical minor histocompatibility antigen as cell-derived peptide. Nature 343(6255):275-278 (Pubitemid 20030646)
3. Palena C, Abrams SI, Schlom J, Hodge JW (2006) Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res 95:115-145 (Pubitemid 44066525)
4. Brichard VA, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178(2):489-495 (Pubitemid 23218197)
5. Kawakami Y, Eliyahu S, Sakaguchi A, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (2004) Identification of the immunodominant peptides of the MART-I human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180(1):347-352
6. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon. T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180(1):35-42 (Pubitemid 24181053)
7. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264(5159):716-719 (Pubitemid 24185883)
8. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van. Pel A, De Plaen. E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-Al by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176(5): 1453-1457
9. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E (1997) Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 158(4): 1796-1802 (Pubitemid 127469536)
10. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3-4):213-219 (Pubitemid 30099526)
11. Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M (2002) HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer 98(6):864-872
12. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163(2):1037-1044 (Pubitemid 29328117)
13. Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT et al (2006) Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55(1):85-95
14. Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K et al (2002) Cellular immunity to the HER-2/neu protooncogene. Adv Cancer Res 85:101-144
15. Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN (2007) Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 121(9):2031-2041 (Pubitemid 47463167)
16. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67(3):1326-1334 (Pubitemid 46270793)
17. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E (1999) Identification, of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59(2):431-435 (Pubitemid 29048879)
18. Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN (2008) Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol 181(1):146-154
19. Brinkman JA, Fausch SC, Weber JS, Kast WM (2004) Peptidebased vaccines for cancer immunotherapy. Expert Opin Biol Ther 4(2): 181-198 Review
20. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML (2002) Vaccination against the HER-2/new oncogenic protein. Endocr Relat Cancer 9(1):33-44 Review (Pubitemid 34298362)
21. Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K (2001) Clinical translation of peptide-based vaccine trials: the HER-2/nen model. Crit Rev Immunol 21(1-3):263-273 Review (Pubitemid 32959365)
22. Murray JL, Przepiorka D, Ioannides CG (2000) Clinical trials of HER- 2/nen-specific vaccines. Semin Oncol 27(6 Suppl l):71-75 discussion 92-100. Review (Pubitemid 32172259)
23. Singh R, Paterson Y (2007) In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 56(6):927-938
24. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F (2006) Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 177(11):7626-7633 (Pubitemid 44846277)
25. Ambrosino E, Spadaro M, lezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F (2006) Immunosurveillanee of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 66(15)7734-7740 (Pubitemid 44289233)
26. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN (2006) Vaccination with human. HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res 66(10):5452-5460
27. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML (2006) IL-2 immunotoxin therapy modulates tumorassociated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177(1):84-91 (Pubitemid 43939119)
28. + T cells to the antitumor immune response. J Exp Med 201(10): 1591-1602
29. Pupa SM, lezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Menard S (2005) Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65(3):1071-1078
30. Quaglino E, Rolla S, lezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R et al (2004) Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 113(5)709-717
31. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from beta2 microglobulin (beta2 m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185(12):2043-2051 (Pubitemid 27265987)
32. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H (2001) PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53(2):87-94
33. Peoples GE, Gurney GM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S (2005) Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23(30)7536-7545 (Pubitemid 46291817)
34. Vertuani SA, Sette A, Sidney J, Southwood S, Fikes J, Keogh E, Lindencrona JA, Ishioka G, Levitskaya J, Kiessling R (2004) Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 172(6):3501-3508
35. Betts MR, Brenchley JM, Price DA, DeRosa SC, Douek DC, Roederer M, Koup RA (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65-78 (Pubitemid 37324571)
36. + regulatory T cells on low/highavidity CD4+ T cells following peptide vaccination. J Immunol 176:6340-6346
37. Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C (2006) Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 12:7476-7482 (Pubitemid 46095423)
38. Rosenberg SA et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4(3):321-327
39. Clay TM et al (1999) Changes in the fine specificity of gpl00(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 162(3): 1749-1755
40. Andersen ML, Ruhwald M, Nissen. MH, Buus S, Claesson MH (2003) Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol 57(1):21-27 (Pubitemid 38019085)
41. McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE (2006) Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin. Invest 116(9):2543-2551
42. Slansky JE et al (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13(4):529
43. + regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm 24(3):357-367
44. Ke X, Wang J, Li L, Chen 1H, Wang H, Yang XF (2008) Roles of CD4+CD25(high) FOXP3+ tregs in lymphomas and tumors are complex. Front Biosci 13:3986-4001 Review (Pubitemid 351594676)
45. Waziri A, Killory B, Ogden AT 3rd, Canoll P, Anderson RC, Kent SC, Anderson DE, Bruce JN (2008) Preferential in situ CD4+CD56+ T cell activation, and expansion within human glioblastoma. J Immunol 180(11)7673-7680
46. Liu L, Wu G, Yao JX, Ding Q, Huang SA (2008) CD4+CD25 high regulatory cells in peripheral blood of cancer patients. Neuro Endocrinol Lett 29(2):240-245
47. highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13(21):6301-6311
48. Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T (2005) CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14(5): 1269-1273
49. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN, Rigatos G, Papamichail M (2007) CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13(9):2714-2721 (Pubitemid 46788040)
50. Goforth R, Salem AK, Zhu X, Miles S, Zhang XQ, Lee JH, Sandler AD (2009) Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother 58(4):517-530
51. Turner MS, Cohen PA, Finn O (2007) Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol 178(5):27872793
52. Klyushnenkova EN, Kouiavskaia DV, Berard CA, Alexander RB (2009) Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection. J Immunol 182(3):1242-1246
53. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF (2005) Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 174(5):2661 (Pubitemid 40279680)
54. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Bancereau J, Ueno H (2007) Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. PNAS 104(52):20884
55. Salazar LG, Coveler AL, Swensen RE, Cooley TA, Goodell V, Schiffman K, Disis ML (2007) Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol 125(3):275-280
56. Mittendorf EA, Peoples GE, Singletary SE (2007) Breast cancer vaccines: promise for the future or pipe dream? Cancer 110(8):1677-1686
57. Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD et al (2006) Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106(11):2309-2317 (Pubitemid 43787653)